Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 2010 (1), CD006605

Long-term Opioid Management for Chronic Noncancer Pain

Affiliations
Review

Long-term Opioid Management for Chronic Noncancer Pain

Meredith Noble et al. Cochrane Database Syst Rev.

Abstract

Background: Opioid therapy for chronic noncancer pain (CNCP) is controversial due to concerns regarding long-term effectiveness and safety, particularly the risk of tolerance, dependence, or abuse.

Objectives: To assess safety, efficacy, and effectiveness of opioids taken long-term for CNCP.

Search strategy: We searched 10 bibliographic databases up to May 2009.

Selection criteria: We searched for studies that: collected efficacy data on participants after at least 6 months of treatment; were full-text articles; did not include redundant data; were prospective; enrolled at least 10 participants; reported data of participants who had CNCP. Randomized controlled trials (RCTs) and pre-post case-series studies were included.

Data collection and analysis: Two review authors independently extracted safety and effectiveness data and settled discrepancies by consensus. We used random-effects meta-analysis' to summarize data where appropriate, used the I(2) statistic to quantify heterogeneity, and, where appropriate, explored heterogeneity using meta-regression. Several sensitivity analyses were performed to test the robustness of the results.

Main results: We reviewed 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as "k"] = 12, n = 3040), transdermally (k = 5, n = 1628), or intrathecally (k = 10, n = 231). Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [95% CI: 4.9% to 27.0%]; intrathecal: 8.9% [95% CI: 4.0% to 26.1%]); or insufficient pain relief (oral: 10.3% [95% CI: 7.6% to 13.9%]; intrathecal: 7.6% [95% CI: 3.7% to 14.8%]; transdermal: 5.8% [95% CI: 4.2% to 7.9%]). Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies.

Authors' conclusions: Many patients discontinue long-term opioid therapy (especially oral opioids) due to adverse events or insufficient pain relief; however, weak evidence suggests that patients who are able to continue opioids long-term experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare.

Conflict of interest statement

None known

Figures

Figure 1
Figure 1
Discontinuation from Oral Opioids Studies due to Adverse Events, Follow‐up 6 months to 24 months (I2=95..8%)
Figure 2
Figure 2
Discontinuation from Transdermal Opioids Studies due to Adverse Events, Follow‐up 6 months to 48 months (I2=97.3%)
Figure 3
Figure 3
Discontinuation from Intrathecal Opioids Studies due to Adverse Events, Follow‐up 20 months (mean) to 29 months (mean) (I2<0.001)
Figure 4
Figure 4
Discontinuation from Oral Opioids Studies due to Insufficient Pain Relief, Follow‐up 7 to 24 months (mean) (I2=81.8%)
Figure 5
Figure 5
Discontinuation from Transdermal Opioids Studies due to Insufficient Pain Relief, Follow‐up 12 to 48 months (I2=52.2%)
Figure 6
Figure 6
Discontinuation from Intrathecal Opioids Studies due to Insufficient Pain Relief, Follow‐up 6 to 29 months (mean) (I2<0.001)
Figure 7
Figure 7
Change in Pain Score from Baseline, Oral Opioids, 6 to 7.5 months (I2=93.9%
Figure 8
Figure 8
Proportion of Patients with at least 50% Pain Relief, Oral Opioids, Follow‐up 7.5 months (mean) to 13 months (I2=77.3%)
Figure 9
Figure 9
Change in Pain Score from Baseline, Transdermal Opioids, Follow‐up 6 months (I2=97.8%)
Figure 10
Figure 10
Proportion of Patients with at least 50% Pain Relief, Transdermal Opioids, Follow‐up 13 months
Figure 11
Figure 11
Change in Pain Score from Baseline, Intrathecal Opioids, Follow‐up 6 months to 29 months (mean) (I2=87.1%)
Figure 12
Figure 12
Proportion of Patients with at least 50% Pain Relief, Intrathecal Opioids, Follow‐up 6 months to 29 months (mean) (I2=71.7%)
Figure 13
Figure 13
Change in Quality of Life from Baseline, Oral Opioids, Follow‐up 13 months
Figure 14
Figure 14
Change in Quality of Life from Baseline, Mental Subscale, Transdermal Opioids, Follow‐up 12 to 13 months (I2=99.0%)
Figure 15
Figure 15
Change in Quality of Life from Baseline, Physical Subscale, Transdermal Opioids, Follow‐up 12 to 13 months (I2=99.1%)
Figure 16
Figure 16
Change in Quality of Life from Baseline, Intrathecal Opioids, Follow‐up 6 to 36 months (I2=93.4%)
Figure 17
Figure 17
Change in Function Levels from Baseline, Intrathecal Opioids, Follow‐up 6 to 36 months (I2=81.2%)

Update of

  • Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006605

Similar articles

  • Long-term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety
    M Noble et al. J Pain Symptom Manage 35 (2), 214-28. PMID 18178367. - Review
    Opioid therapy for chronic noncancer pain (CNCP) is controversial due to concerns regarding long-term efficacy and adverse events (including addiction). We systematically …
  • Opioids for Neuropathic Pain
    ED McNicol et al. Cochrane Database Syst Rev 2013 (8), CD006146. PMID 23986501. - Review
    Since the last version of this review, new studies were found providing additional information. Data were reanalyzed but the results did not alter any of our previously p …
  • Oral or Transdermal Opioids for Osteoarthritis of the Knee or Hip
    BR da Costa et al. Cochrane Database Syst Rev (9), CD003115. PMID 25229835. - Review
    The small mean benefit of non-tramadol opioids are contrasted by significant increases in the risk of adverse events. For the pain outcome in particular, observed effects …
  • Opioids for Acute Pancreatitis Pain
    X Basurto Ona et al. Cochrane Database Syst Rev (7), CD009179. PMID 23888429. - Review
    Opioids may be an appropriate choice in the treatment of acute pancreatitis pain. Compared with other analgesic options, opioids may decrease the need for supplementary a …
  • Oral Analgesia for Relieving Post-Caesarean Pain
    N Mkontwana et al. Cochrane Database Syst Rev (3), CD010450. PMID 25821010. - Review
    Eight trials with 962 women were included in the analysis, but only four trials were of high quality. All the trials were small. We carried out subgroup analysis for diff …
See all similar articles

Cited by 180 PubMed Central articles

See all "Cited by" articles

Substances

Feedback